Press Release | Tue Oct 1, 2013 8:00am EDT

Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration

* Reuters is not responsible for the content in this press release.